Estimated effects of amyloid reduction on cognitive change: A Bayesian update across a range of priors
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Estimated effects of amyloid reduction on cognitive change: A Bayesian update across a range of priors
Authors
Keywords
-
Journal
Alzheimers & Dementia
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2023-10-31
DOI
10.1002/alz.13470
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lecanemab trial in AD brings hope but requires greater clarity
- (2023) Madhav Thambisetty et al. Nature Reviews Neurology
- Need for truthfulness in dementia research
- (2023) Timothy P Daly BMJ-British Medical Journal
- Alzheimer’s disease: FDA approves lecanemab amid cost and safety concerns
- (2023) Elisabeth Mahase BMJ-British Medical Journal
- Unblinding in the lecanemab trial in Alzheimer's disease
- (2023) Willem A Van Gool BRAIN
- Accelerated Brain Volume Loss Caused by Anti–β-Amyloid Drugs
- (2023) Francesca Alves et al. NEUROLOGY
- Advocating for Demonstration of Disease Modification—Have We Been Approaching Clinical Trials in Early Alzheimer Disease Incorrectly?
- (2023) Vincent Planche et al. JAMA Neurology
- Donanemab in Early Symptomatic Alzheimer Disease
- (2023) John R. Sims et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
- (2022) Eric Karran et al. NATURE REVIEWS DRUG DISCOVERY
- Ventricular enlargement caused by aducanumab
- (2022) Scott Ayton Nature Reviews Neurology
- Effect of reduction in brain amyloid levels on change in cognitive and functional decline in randomized clinical trials: An instrumental variable meta‐analysis
- (2022) Menglan Pang et al. Alzheimers & Dementia
- High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects
- (2022) N. Villain et al. REVUE NEUROLOGIQUE
- High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 2: putative scenarios and timeline in case of approval, recommendations for use, implementation, and ethical considerations in France
- (2022) N. Villain et al. REVUE NEUROLOGIQUE
- An Ethical Argument for Ending Human Trials of Amyloid-Lowering Therapies in Alzheimer’s Disease
- (2022) Timothy Daly et al. AJOB Neuroscience
- Comment on “Effect of reduction in brain amyloid levels on change in cognitive and functional decline in randomized clinical trials: An updated instrumental variable meta‐analysis”
- (2022) Sarah F Ackley et al. Alzheimers & Dementia
- Relationship between beta‐amyloid (Ab) plaque reduction and clinical benefit: the rationale for aducanumab approval
- (2022) Yaning Wang Alzheimers & Dementia
- Lecanemab in Early Alzheimer’s Disease
- (2022) Christopher H. van Dyck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of monomeric amyloid-β in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies
- (2022) Bruno P. Imbimbo et al. PHARMACOLOGICAL RESEARCH
- Lecanemab trial finds slight slowing of cognitive decline, but clinical benefits are uncertain
- (2022) Elisabeth Mahase BMJ-British Medical Journal
- Lecanemab for Alzheimer’s disease
- (2022) Sebastian Walsh et al. BMJ-British Medical Journal
- Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis
- (2021) Sarah F Ackley et al. BMJ-British Medical Journal
- Instrumental variable meta-analysis of aggregated randomized drug trial data for evaluating proposed target mechanisms
- (2021) Sarah F Ackley et al. BMJ-British Medical Journal
- Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease
- (2021) Konstantinos I. Avgerinos et al. AGEING RESEARCH REVIEWS
- Bayes analysis supports null hypothesis of anti‐amyloid beta therapy in Alzheimer's disease
- (2021) Edo Richard et al. Alzheimers & Dementia
- Cognitive outcomes of anti‐amyloid‐β monoclonal antibodies in patients with Alzheimer's disease: A systematic review and meta‐analysis of randomized controlled trials
- (2021) Paulo Eduardo Lahoz Fernandez et al. Alzheimers & Dementia
- What the Aducanumab Approval Reveals About Alzheimer Disease Research
- (2021) Jennifer J. Manly et al. JAMA Neurology
- Implementing the centiloid transformation for 11C-PiB and β-amyloid 18F-PET tracers using CapAIBL
- (2018) Pierrick Bourgeat et al. NEUROIMAGE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now